Exagen (NASDAQ:XGN) Stock, Quote.Headers.trade-ideas

Exagen

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Earnings

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

APDN

HCAT

Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors&#39; minds. This is because investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio.

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Pre-Market Outlook

With US futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:


Nike, Tencent Music Entertainment And 3 Stocks To Watch Heading Into Tuesday

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Biotech

General

COYA

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and c

Coya Therapeutics&#39; Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Exagen Inc

Press Releases

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Exagen Inc. Reports Third Quarter 2024 Results

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Health Care

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Adicet Bio

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

BeyondSpring

Cibus

Cue Biopharma

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Inozyme Pharma

IO Biotech

Kronos Bio

Metagenomi

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

PMV Pharma

Pyxis Oncology

Quince Therapeutics

Skye Bioscience

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Cantor Fitzgerald

Canaccord Genuity

BTIG

Keybanc

Comments

Exagen

Exagen (NASDAQ:XGN) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga